#EULAR2022
13 سلاسل التغريدات
#EULAR2022 What is New (WIN) IgG4 🔆IgG4 is a multi-organ Disease 🔆usually >50 🔆M:F - 3:1 🔆CD4+ cytotoxic cell implicated 🔆 Classification criteria known https://t.co/6bfxNJNlPt
#EULAR2022 How To Treat (HOT) Anti-phospholipid syndrome https://t.co/QohcGqQ9Qj
#EULAR2022 New treatment strategies and approaches to young adults with inflammatory myositis Treatment options available their doses in IIM https://t.co/g5YI0U1X8p
#EULAR2022 Contrasts in pathomechanisms and treatment targets between adult and paediatric inflammatory myositis 👁🗨 Awesome class on IIM pathogenesis 👁🗨The MSA and Phenotype Sl...
#EULAR2022 From Bench to Bedside Sjogren syndrome: from biopsy to lymphoma 🟢 Sjogren's has the highest risk of Lymphoma among all AIRDs 🟢The risk is not as high as earlier thought...
#EULAR2022 Joint and skin involvement in SLE Treatment of CLE 👉🏻 Algorithm and available Rx https://t.co/nJXAJViN6y
#EULAR2022 JAK inhibitors: are all promises fulfilled? Most Physicians Prefer JAKi due to 🔹 Good Efficacy 🔹 Faster onset of action 🔹 Better adherence (50% attrition for JAK at 4...
📌📌Manifestaciones no criterio del SAF: ¿cómo debemos abordarlas y tratarlas? 🧐 #EULAR2022 @karlita_chacon_ @ColMexReuma 🔷Manifestaciones no criterio:enfermedad valvular cardíaca🫀...
#EULAR2022 WIN session Sarcoidosis – an update for rheumatologists https://t.co/m2pOVzf3ka
#EULAR2022 How to Manage (HOT): Lupus Nephritis What is High risk LN https://t.co/R44vscOelj
#EULAR2022 WIN Session From pathogenesis to new therapies: what is new in SLE? 🔹Disease activity pathway to control damage/death 🔹Still a major cause of death in young women 🔹We...
#EULAR2022 EULAR Recommendations session RA-Treatment Guidelines Principles Remain the Same 1st 5 recommendations Remain the same https://t.co/grKfZks2OU